This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

1LV Stock Overview

Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. More details

1LV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 60.32% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Shareholders have been diluted in the past year

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Satsuma Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Satsuma Pharmaceuticals
Historical stock prices
Current Share Price	US$0.93
52 Week High	US$0.98
52 Week Low	US$0.59
Beta	0.10
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-96.17%
5 Year Change	n/a
Change since IPO	-96.45%

Recent updates

Shareholder Returns

	1LV	DE Pharmaceuticals	DE Market
7D	0%	-6.6%	0.5%
1Y	n/a	-27.8%	14.4%

Return vs Industry: Insufficient data to determine how 1LV performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1LV performed against the German Market.

Price Volatility

Is 1LV's price volatile compared to industry and market?
1LV volatility
1LV Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 1LV has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 1LV's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	25	John Kollins	www.satsumarx.com

Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company’s product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Satsuma Pharmaceuticals, Inc. Fundamentals Summary

How do Satsuma Pharmaceuticals's earnings and revenue compare to its market cap?
1LV fundamental statistics
Market cap	€33.83m
Earnings (TTM)	-€60.14m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Is 1LV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1LV income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$64.83m
Earnings	-US$64.83m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.96
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 1LV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/09 00:35
End of Day Share Price	2023/04/20 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Satsuma Pharmaceuticals, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yifan Ye	CLSA
Evan Seigerman	Credit Suisse
Michael DiFiore	Evercore ISI

Satsuma Pharmaceuticals MUN:1LV Stock Report